Neuroendocrine Prostate Cancer Market Forecast Highlights Expansion From $1.14 Billion To $1.6 Billion Through 2030
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Neuroendocrine Prostate Cancer Market Size, Value And Growth Trends Through 2030
The neuroendocrine prostate cancer market size has experienced significant expansion in recent years. It is forecast to rise from $1.05 billion in 2025 to $1.14 billion by 2026, achieving a compound annual growth rate (CAGR) of 8.5%. The historical growth of this market can be ascribed to a rise in prostate cancer diagnosis, long term hormone therapy resistance, expansion of oncology drug pipelines, growth of molecular pathology testing, and increased cancer center specialization.
The neuroendocrine prostate cancer market size is anticipated to undergo significant growth in the coming years. It is forecast to reach $1.6 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This projected growth throughout the forecast period is driven by increasing adoption of precision oncology, the rise of biomarker-based treatments, the expansion of targeted therapies, heightened funding for rare cancer research, and broader utilization of genomic testing. Major developments expected during this period include biomarker-driven patient stratification, protocols for combination oncology therapy, advanced molecular diagnostic testing, an increase in rare cancer clinical trials, and targeted radiopharmaceutical approaches.
Download A Free Sample Report For Comprehensive Market Insights:
Neuroendocrine Prostate Cancer Market Expansion Supported By Key Demand Factors
The neuroendocrine prostate cancer market is projected to expand owing to the increasing occurrence of prostate cancer. This malignant tumor, which develops in the prostate gland primarily affecting men over 50, is seeing a rise in prevalence largely because of the growing aging male population, a key risk factor for its development. The elevated prevalence of prostate cancer supports the growth of the neuroendocrine prostate cancer market by expanding the total patient pool, increasing prolonged exposure to androgen-deprivation therapies, and thereby raising the probability of treatment-induced neuroendocrine differentiation in advanced and castration-resistant disease stages. For example, in January 2025, the Centers for Disease Control and Prevention (CDC), a U.S. federal public health agency, reported that in 2023, 255,395 new cases of prostate cancer were diagnosed in the United States, and 33,881 men died from the disease. Consequently, the increasing prevalence of prostate cancer is fostering the growth of the neuroendocrine prostate cancer market.
Neuroendocrine Prostate Cancer Market Segments: Where Are The Largest Growth Opportunities?
The neuroendocrine prostate cancer market covered in this report is segmented –
1) By Treatment: Chemotherapy; Hormonal Therapy
2) By Therapeutics: Immunotherapy; Targeted Therapy
3) By Disease Stage: Localized Disease; Advanced Disease; Metastatic Disease
4) By End Users: Hospitals; Oncology Specialty Clinics; Cancer Research Institutes
Subsegments:
1) By Chemotherapy: Platinum Based Chemotherapy; Taxane Based Chemotherapy; Combination Chemotherapy; Second Line Chemotherapy
2) By Hormonal Therapy: Androgen Deprivation Therapy; Androgen Receptor Inhibition; Hormone Synthesis Inhibition; Combined Hormonal Therapy
Neuroendocrine Prostate Cancer Market Growth Trends Influencing Competitive Dynamics
Leading companies in the neuroendocrine prostate cancer market are concentrating on creating novel medications, including immune-modulating small-molecule therapies, with the aim of boosting immune response and achieving better patient results. These immune-modulating small-molecule therapies are compounds taken orally that work by stimulating the body’s natural immune system to identify and combat cancer cells, thereby helping to overcome resistance often seen with conventional treatments like hormone therapy or chemotherapy by strengthening the immune system’s anti-tumor activity. As an example, BioXcel Therapeutics, a clinical-stage biopharmaceutical firm based in the US, was granted Fast Track Designation by the U.S. Food and Drug Administration in February 2024 for BXCL701, an immune-modulating small-molecule therapy designed for neuroendocrine prostate cancer. BXCL701 is specifically engineered to activate the NLRP3 inflammasome, augment cytokine release, and prepare the immune system to target tumor cells, thereby presenting an innovative strategy that works alongside immune checkpoint inhibitors. This Fast Track Designation is anticipated to expedite the clinical development and regulatory assessment of BXCL701, underscoring its potential to address considerable unmet medical requirements in cases of aggressive and treatment-resistant prostate cancer.
Neuroendocrine Prostate Cancer Market Major Participants And Competitive Dynamics
Major companies operating in the neuroendocrine prostate cancer market are Novartis AG, Amgen Inc., Phanes Therapeutics Inc., and BioXcel Therapeutics Inc.
Access The Complete Neuroendocrine Prostate Cancer Market Report:
Neuroendocrine Prostate Cancer Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the neuroendocrine prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
